Peginterferon Alfa-2A
| Evidence Level: L1 | Predicted Indications: 9 |
Table of Contents
Peginterferon Alfa-2A: Hepatitis E virus infection
One-Sentence Summary
Peginterferon alfa-2a is a pegylated interferon originally used to treat chronic hepatitis C and chronic hepatitis B. The TxGNN model (deep learning) predicts it may be effective for hepatitis E virus infection, with a score of 0.9983. The prediction is supported by 20 clinical trials and 20 publications, including a pivotal RCT.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hepatitis E virus infection |
| TxGNN Prediction Score | 0.9983 |
| Evidence Level | L1 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, peginterferon alfa-2a is a type I interferon. It acts through interferon receptor signalling and induction of interferon-stimulated genes, giving both antiviral and immunomodulatory effects. This is the mechanism underlying its activity in chronic hepatitis B.
Chronic hepatitis B is already listed among the drug’s original indications, so the prediction confirms an existing use. It is supported by Phase 3 and Phase 4 trials and a pivotal RCT (PMID 15987917).
Other lower-ranked predictions (hepatitis E, hepatitis A, Omsk haemorrhagic fever, Kyasanur forest disease, and several cardiac conditions) have little or no direct evidence. They are not recommended for further pursuit at this time (see Conclusion).
Clinical Trial Evidence
Twenty trials were linked to this prediction. The most relevant are listed below (up to 10). Many are small or uncontrolled, and several are post-marketing or observational studies.
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02604823 | Phase 4 | Completed | 307 | Efficacy and safety of peginterferon alfa-2a for 48 weeks in HBeAg-positive chronic hepatitis B, with 24 weeks of follow-up |
| NCT00614471 | Phase 4 | Completed | 219 | Randomised comparison of peginterferon alone versus combination or sequential entecavir in treatment-naive HBeAg-positive patients |
| NCT02474316 | Phase 4 | Unknown | 366 | Switching NA-treated HBeAg-positive patients to peginterferon plus NA versus entecavir alone for 48 weeks |
| NCT03181113 | N/A | Completed | 473 | Long-term follow-up cohort of HBeAg-positive patients previously treated with peginterferon |
| NCT02097004 | Phase 4 | Completed | 111 | Therapeutic vaccination plus peginterferon for HBsAg seroclearance in entecavir-suppressed patients |
| NCT03084250 | Phase 4 | Unknown | 150 | Randomised study of NA plus peginterferon versus NA alone in cirrhotic patients at high risk of hepatocellular carcinoma |
| NCT00436163 | Phase 4 | Completed | 39 | Single-arm Baltic post-marketing programme in HBeAg-positive and HBeAg-negative patients |
| NCT00661076 | Phase 3 | Completed | 10 | Peginterferon plus adefovir versus peginterferon alone in HBeAg-negative patients (very small sample) |
| NCT01237496 | Phase 3 | Completed | 17 | Immunology sub-study of HBV-specific T cell responses in HBeAg-negative patients |
| NCT02570191 | Phase 4 | Completed | 60 | Open-label, non-randomised study in HBeAg-negative chronic hepatitis B |
No ANZCTR identifiers were found in the data compiled for this report.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15987917 | 2005 | RCT | N Engl J Med | Peginterferon alfa-2a with or without lamivudine versus lamivudine alone in HBeAg-positive chronic hepatitis B |
| 30549279 | 2019 | RCT | Hepatology | Entecavir plus peginterferon alfa-2a in adults with HBeAg-positive immune-tolerant chronic hepatitis B |
| 30865588 | 2019 | Meta-analysis | Antivir Ther | Individual participant data meta-analysis to identify treatment stopping rules for peginterferon in chronic hepatitis B |
| 26299874 | 2016 | Meta-analysis | Clin Res Hepatol Gastroenterol | Extended versus standard 48-week duration of peginterferon alfa-2a monotherapy |
| 33720089 | 2021 | Randomised controlled study | J Pediatr Gastroenterol Nutr | Peginterferon plus lamivudine or entecavir in children with immune-tolerant chronic hepatitis B |
| 30318613 | 2019 | Clinical trial | Hepatology | Entecavir plus peginterferon in children with HBeAg-positive immune-tolerant infection |
| 26700861 | 2015 | Randomised trial | Virol J | Long-term effects of peginterferon alfa-2a in Japanese patients with chronic hepatitis B |
| 32548156 | 2020 | Cohort | World J Clin Cases | Cytokines predict virological response to peginterferon alfa-2a |
| 18845489 | 2008 | Guideline/Review | Clin Gastroenterol Hepatol | Updated US treatment algorithm for chronic hepatitis B |
| 19084016 | 2009 | Clinical study | Gastroenterology | Peginterferon alfa-2a plus ribavirin in dual chronic HBV and HCV infection |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11037X | Pegasys | Injection 180 micrograms in 0.5 mL single use pre-filled syringe | Not recorded in the data compiled for this report |
Safety Considerations
- Drug Interactions: 100 interactions were identified. Those shown below are drawn from the first 20 returned and are not exhaustive.
- Major: bupropion, deferiprone, iopamidol, iohexol, samarium (153Sm) lexidronam, eltrombopag
- Moderate: metronidazole, tinidazole, picosulfuric acid, polyethylene glycol (3350 with electrolytes), sodium sulfate, pegvaliase, naltrexone, rosuvastatin, simvastatin, warfarin, dicoumarol, chloroquine, palifermin, strontium chloride Sr-89
- Other safety observations: Interferon therapy is associated with neuropsychiatric effects such as depression (a preclinical rat study, PMID 17049181, examined this) and with cardiovascular adverse effects such as arrhythmia.
Warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Hepatitis B virus infection is already an established use of peginterferon alfa-2a. It is supported by multiple Phase 3 and Phase 4 trials, several meta-analyses and a pivotal RCT, which is consistent with Evidence Level L1. However, many linked trials are small or uncontrolled, and the ARTG entry has no recorded indication text and no available PI warnings. Under the decision framework used for this report, this lack of safety information blocks progression to safety screening, so the recommendation is conditional rather than unqualified.
The other predicted indications are not recommended (Hold). Hepatitis E (L4) and hepatitis A (L5) have only indirect or no relevant evidence, since the linked trials studied HBV or HCV. The animal viral hepatitis concept (L4) is not a human indication. Omsk haemorrhagic fever and Kyasanur forest disease (L5) are unvalidated predictions. The cardiac conditions (L5) appear to be TxGNN model (deep learning) artefacts, and interferon’s cardiovascular adverse effects are a more plausible concern than a benefit.
To proceed, the following is needed:
- The TGA-approved PI, to confirm the registered indications, warnings and contraindications for ARTG 11037X
- Detailed mechanism of action data (MOA)
- Confirmation that the Australian approved indication covers chronic hepatitis B, and review of current Australian treatment guidelines
- A safety monitoring plan covering neuropsychiatric, cardiovascular and haematological effects, and a review of the major drug interactions listed above
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.